Table 1 Patient characteristics and number of genomic alterations detected in ctDNA among pancreatic ductal adenocarcinoma patients (N = 112)
From: Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
Characteristics for all patients [N = 112] | N (%) | ||
 Median age (range) (years)* | 67.8 (38.0–92.7) | ||
 Gender |  | ||
  Men | 60 (53.6%) | ||
  Women | 52 (46.4%) | ||
 Ethnicity |  | ||
  Caucasian | 76 (67.9%) | ||
  Hispanic | 16 (14.3%) | ||
  Asian | 7 (6.3%) | ||
  African American | 4 (3.6%) | ||
  Other/unknown | 9 (8.0%) | ||
 Disease status at the time of blood draw |  | ||
  Advanced (metastatic, locally advanced or recurrent disease) | 94 (83.9%) | ||
  Preoperative (surgically resectable, blood obtained before surgery) | 10 (8.9%) | ||
  Postoperative (surgically resectable, blood obtained after surgery) | 8 (7.1%) | ||
 Number of patients with ≥ 1 characterized alteration | 78 (69.6%) | ||
 Median number of characterized alterations per patient (range) | 1 (0–6) | ||
Comparisons of ctDNA results between advanced cases and preoperative cases** | |||
Parameters | Advanced cases (N = 94) | Preoperative cases (N = 10) | P value |
Number of characterized alterations per patient (range), median (range) (%) | 2 (0–6) | 0.5 (0–3) | 0.04 |
No. of patients with detectable characterized alterations | 70 (74.5%) | 5 (50.0%) | 0.14 |
Maximum %ctDNA per patient (characterized alterations), median (range) (%) | 0.4 (0.0–64.6) | 0.0 (0.0–0.62) | 0.02 |
Total %ctDNA per patient (characterized alterations), median (range) (%) | 0.6 (0.0 - 92.05) | 0.0 (0.0 - 0.70) | 0.007 |